A-Share Pre-Market Brief | 2026-10-07 Wednesday

Special statement: today (10/7) is the final day of the A-share National Day holiday (market closed 10/1–10/7; trading resumes Thursday 10/8) — there is no session today. This list is the final pre-market watch list for 10/8, the first post-holiday day (yesterday's list: reports/a-share/2026-10-06.md; this list keeps only judgments that still hold and makes incremental updates on that basis). Time window: the entire holiday starting 9/30 15:00, with focus on increments after 10/6 07:00 (yesterday's list publication).

0. Today's One-Line Summary

Ahead of the holiday's final verification night, the news flow has formed two main lines: ① innovative drugs / BD going overseas — HK stocks exploded across the board on 10/6 (CanSino Biologics (06185.HK) single-day +14.04%, Hang Seng Biotech Index at a new year high), the only main line validated by overseas markets on multiple consecutive days during the holiday (rebounding on 10/5 and 10/6 after the 10/2 liquidity-driven mispricing sell-off); ② memory supercycle — Micron's FY2026Q4 blockbuster earnings (revenue +379% y/y, next-quarter guidance continuing to rise sharply q/q, verified against the IR press release), a new branch missed by yesterday's list and upgraded to S tier in this list. Likely capital directions: pharma (innovative drugs + vaccines) + computing hardware (memory/PCB/optical modules). Driver type: overseas industry mapping + earnings. Pre-market status call: 10/8 will most likely see a structural gap-up, but two constraints remain — the 10Y UST closed at 5.31% on 10/5, a 52-week high (intraday 5.35%, the highest since 2002, only falling back to ~5.28% in the 10/6 Asian session), and the holiday HK main-board turnover was below HK$100 billion on both days (thin-volume rebound: just HK$98.265 billion on 10/6); the size of the gap-up determines profit-taking risk, and auction volume matters more than direction.

Macro switch (same framework as yesterday): a 10Y UST >5.40% triggers down-weighting of the high-valuation branch. Currently 5.28%–5.31%, not triggered but closer than yesterday. The contradictory backdrop data must be faced head-on: September nonfarm payrolls of only +29k (vs. +84k expected) slashed the odds of an October Fed rate hike from 71% a week earlier to 24% (CME FedWatch), yet the 10Y hit a 52-week high the same day — cooling rate-hike expectations and rising long-end yields point in opposite directions, possibly reflecting a tug-of-war between fiscal supply/term premium and dovish data expectations (the driver is not explained by a single variable; judgment caliber); the US dollar index fell 0.33% to 101.83 in NY forex on 10/6. Tonight 10/7: three US Treasury auctions + the Fed minutes (early Thursday morning Beijing time) are the last macro observation window before the open.

1. News Overview

Time window: after 9/30 15:00 (the entire holiday); ★ = increments after 10/6 07:00 (yesterday's list). Note: the impact grade is the score of a single news item, while branch strength is an aggregation of multiple items; the two are allowed to differ.

2. Strongest Positive Branches, Descending

Key points by branch: Innovative drugs — the only main line continuously validated by overseas markets during the holiday, confirmed by the 10/6 HK close (CanSino H single-day +14%, Hang Seng Biotech at a year high), and ESMO on 10/23 forms a confirmed post-holiday event relay; but note the internal split — Hengrui H actually fell 3.6% over the holiday, meaning the "BD positive" has been partly digested in HK, so the "freshness discount" on the 10/8 A-share gap-up must be priced in. Memory — Micron's earnings are the hardest industry data of the holiday (missed by yesterday's list); the H1 earnings elasticity of A-share mapped names has genuinely been delivered (GigaDevice H1 net profit +1091%), but the sector is a strong cyclical and chasing it means accepting high volatility; structurally servers are strong and consumer weak, so individual-stock divergence may appear in Q4. Computing hardware — both boom and sentiment are present (NVIDIA record + dense model launches), but A-share electronics just had a high-volume selloff on 9/30; 10/8 is the judgment day for "repair or dead-cat bounce" — auction volume decides. Gold — yesterday's "gold at new highs" caliber, after verification, does not hold (US$4,170 is the old October 2025 high; currently ~US$4,140–4,190, ~26% below the January peak), so this list downgrades it to B+ and re-frames it as a "rebound from a low within the month"; gold miners' fundamentals (Zijin H1 +68%) remain solid, but it is no longer a "new-high elasticity" story. Oil tanker shipping — freight rate data (US$631k/day, the latest available value for the week of 9/18) is harder than oil price data, and the EIA's upgraded oil forecast is also positive, but Brent breaking US$100 weighs on sentiment; maintain "buy pullbacks, don't chase."

3. Stock Positive-Strength Leaderboard (descending by stock)

4. Stock Scoring Model (total 100)

Components: source authority 0–15 / benefit directness 0–20 / earnings elasticity 0–15 / industry position & fundamentals 0–15 / expectation gap 0–10 / theme sustainability 0–10 / A-share trading profile 0–10 / risk deduction 0 to −15. Financials are all 2026 H1 reports (akshare measured); PE-TTM is at the 9/30 close caliber (no A-share trading after 9/30; a few stocks use the 10/6 valuation caliber).

Full sub-scores (format: authority/directness/elasticity/position/gap/sustainability/trading/risk deduction): Hengrui Medicine 15/19/13/15/8/9/9/−4=84; WuXi AppTec 14/16/13/15/7/9/9/−1=82; GigaDevice 14/18/14/14/7/8/8/−5=78; Shengyi Technology 14/15/13/14/6/8/8/−6=72; Longsys 14/17/14/12/7/8/8/−8=72; Victory Giant 13/15/12/12/6/8/9/−5=70; WUS Printed Circuit 13/14/12/13/6/8/8/−4=70; COSCO Shipping Energy 12/16/13/13/5/7/7/−5=68; Zijin Mining 13/14/12/14/6/7/8/−6=68; Montage Technology 13/13/11/13/7/8/7/−5=67; Innolight 13/13/11/13/6/8/8/−6=66; PetroChina 12/13/11/14/5/7/7/−4=65; Kelun Pharmaceutical 13/13/10/12/8/7/7/−7=63; CanSino 13/9/8/11/7/9/10/−5=62; Pharmaron 12/12/9/12/6/7/7/−4=61; ICBC 12/12/9/14/5/6/7/−4=61; Lygend Resources 12/13/12/11/6/6/8/−7=61; Shandong Gold 12/13/11/12/4/6/7/−5=60; TFC Communication 12/12/10/12/5/7/7/−5=60; SMEC 12/11/10/10/7/6/7/−6=57; Vanke A 11/7/4/12/5/6/8/−7=46; Shenzhen Properties A 11/6/4/7/5/6/10/−7=42.

Note: the positive grade (S/A+/A/…) describes the strength of the news itself, while the total is the sum of the eight realization paths — the two are allowed to diverge: CanSino's news grade is A+ (an H-share single-day +14% sentiment event) but its benefit directness scores only 9 (the company itself says commercialization needs 3–5 years), total 62; COSCO Shipping Energy's grade is A− but its expectation gap is low (trend already recognized), total 68, still "watch for support" rather than "chase."

5. Top 10 Stocks in Detail

51 恒瑞医药600276total 84, priority deep-dive · Hengrui Medicine · Shanghai main board

• Related news: 9/29–9/30 announcement: HRS-1596 (oral GLP-1/GIP dual-target, Phase I approved in China) overseas rights licensed to Novo Nordisk, US$0.3 billion upfront + milestones up to US$2.3 billion + sales royalties, closing expected 2026Q4 (Economic Reference³⁶, Yicai³⁷); ESMO 10/23: its HER3 ADC Phase III data granted an LBA oral presentation (media caliber).
• Positive logic: Direct. The ~RMB 2.1 billion upfront is expected to be recognized in Q4 (Citi estimate, media caliber), ≈27% of FY2025 full-year net profit attributable to parent — it hits revenue, not pure sentiment; it also provides international pricing endorsement for the GLP-1 pipeline.
• Industry branch stage: innovative-drug BD going overseas, main upward leg; the 10/6 HK explosion validates the sector's status; the branch has echelons (CanSino 20CM, Kelun ESMO elasticity) and a core anchor (WuXi AppTec).
• Fundamentals check: 2026H1 revenue RMB 15.456 billion (−1.94%, media reports the first negative print in years), net profit attributable to parent RMB 4.465 billion (+0.34%), ex-non-recurring RMB 3.73 billion (−12.71%, centralized procurement + high base from last year's BD), gross margin 86.3%, debt ratio 8.2%, operating cash flow RMB 1.987 billion; innovative-drug revenue RMB 8.809 billion (+16.4%), 63% of drug revenue. PE-TTM ~40.6x.
• Industry position: domestic innovative-drug #1, strongest BD delivery capability.
• Technicals / sentiment: main board ±10%; 9/30 +3.46%, no climax; but H shares (01276.HK) fell ~3.6% cumulatively over the holiday (−2.58% on 10/5, flat on 10/6), meaning the BD positive has been partly digested in HK — the direct reason this list cuts its "expectation gap" score by 1.
• Final call: the stock with the hardest holiday catalyst and a Q4 revenue-recognition expectation (broker caliber). 10/8 watch points: gap-up ≤3% with volume = healthy; gap-up above 5%, watch the pullback for support; if H shares keep weakening tonight (HK still trading on 10/7), lower auction expectations in sync.

52 药明康德603259total 82, priority deep-dive · WuXi AppTec · Shanghai main board

• Related news: 10/6 H shares closed HK$218.60, +2.92%; WuXi Biologics +4.5%; JPMorgan research says "not too worried about rates' impact on CRO" (Zhitong³⁸); same day the WuXi complex / Innovent ranked top-3 in HK short-selling value (divergence widening, Stockstar¹¹).
• Positive logic: Direct. Orders, revenue, profit, cash flow — fourfold verification; no single blockbuster, but the highest certainty.
• Industry branch stage: CXO boom recovery confirmation phase; the "core anchor" of the innovative-drug main line.
• Fundamentals check: 2026H1 revenue RMB 28.897 billion (+38.9%), net profit attributable to parent RMB 11.08 billion (+29.4%, ex-non-recurring +89.4%), gross margin 53.9% rising year by year, operating cash flow RMB 9.699 billion, debt ratio 27.9%; backlog RMB 66.43 billion (+25.2%) at a record; TIDES revenue RMB 7.26 billion (+44.3%); full-year guidance raised to RMB 58.5–60.5 billion. PE-TTM ~23.4x, the most "solid" among this list's verified stocks. Red flag: accounts receivable RMB 10.47 billion (+44%); geopolitical legislative risk.
• Industry position: global CRDMO leader, the absolute CXO core of A-shares.
• Technicals / sentiment: 9/30 +4.16%, main-force net inflow over RMB 0.8 billion; 10/6 HK kept rising but short-selling topped — climbing amid divergence.
• Final call: the best risk-reward large-cap in the innovative-drug main line; use as the sector observation's core anchor; verification points are the 10/8 auction gap-up size and northbound/institutional support.

53 兆易创新603986total 78, priority deep-dive · GigaDevice · Shanghai main board

• Related news: Micron FY26Q4 revenue US$54.229 billion, +379.3% y/y, GAAP gross margin 86.8%, FY27Q1 guidance US$61.5±1.5 billion revenue, gross margin ~86% (Micron IR press release³, verified item by item in this list); CEO says FY27 will be even stronger, memory supply-demand significantly tighter in 2027–2028.
• Positive logic: Direct. Niche DRAM/NOR price-hike elasticity already delivered in H1 reports; Micron's earnings and guidance are the "master switch" of global memory pricing, directly improving sector earnings expectations.
• Industry branch stage: memory supercycle main upward leg (branch missed by yesterday's list, upgraded to S− in this list).
• Fundamentals check: 2026H1 revenue RMB 11.566 billion (+178.7%), net profit attributable to parent RMB 6.857 billion (+1091.5%), ex-non-recurring RMB 4.883 billion; gross margin 63.1% (vs. 37.2% a year earlier); operating cash flow RMB 6.048 billion; debt ratio 11.5%; inventory RMB 4.18 billion (only 10% of total assets, healthy structure, in contrast to Longsys). PE-TTM ~31.4x.
• Industry position: domestic NOR Flash #1, niche DRAM ramping with ChangXin synergy.
• Technicals / sentiment: 9/30 −3.72% followed electronics down, not overdrawn; main board ±10%.
• Final call: the most balanced "earnings-valuation-structure" name in the memory branch; the risk is Morgan Stanley's August caliber expecting Q4 consumer DRAM price gains to narrow to 0–5% — structural divergence; on 10/8, watch whether the auction can gap up with volume above the 9/30 bearish candle high.

54 生益科技600183total 72, priority deep-dive (watch pullback support) · Shengyi Technology · Shanghai main board

• Related news: Kingboard Laminates (01888.HK) +11.94% on 10/5 (STCN 10/5³⁹), then fell just 0.36% on 10/6 on shrinking volume, resilient (10jqka HK close 10/6³⁴); 7 rounds of CCL price hikes YTD (Kingboard-led, cumulative >40%, media caliber); NVIDIA +2% to a new high on 10/5.
• Positive logic: Direct. The core logic (high-speed board volume ramp + price hikes) has been delivered for multiple consecutive quarters; the HK move is only a mapping catalyst.
• Industry branch stage: a repair bet after computing hardware's 9/30 fade; 10/8 is the judgment day for "repair or dead-cat bounce."
• Fundamentals check: 2026H1 revenue RMB 19.026 billion (+50.1%), net profit attributable to parent RMB 3.287 billion (+130.4%), gross margin 30.7% climbing continuously, operating cash flow RMB 2.983 billion; debt ratio 50.3% (balance-sheet expansion for capacity); April announcement: RMB 5.2 billion high-performance CCL capacity expansion; the only domestic NVIDIA M9 high-speed substrate certification (industry media caliber, not confirmed by company announcement). Red flag: PE-TTM ~60.8x, valuation already prices in substantial price-hike expectations.
• Industry position: global rigid CCL #2, China #1.
• Technicals / sentiment: 9/30 −2.27%, far smaller drop than the limit-down PCB high-flyers; main board ±10%.
• Final call: the stock with the most real delivery path in the PCB repair branch. Gap-up ≤3% + auction volume = healthy; gap-up above 5%, wait for the pullback; if the PCB sector shows no auction volume, treat it as a dead-cat bounce.

55 江波龙301308total 72, watch closely · Longsys · ChiNext

• Related news: Same Micron earnings (memory modules fully tied to the price cycle); Micron says it signed strategic long-term agreements with key customers to lock volume; product side: 512GB DDR5 RDIMM sampling (Micron IR³).
• Positive logic: Direct and the most elastic — module makers are the profit amplifier of a price-hike cycle; H1 already delivered stunning elasticity.
• Industry branch stage: high-beta elasticity name in the memory main upward leg.
• Fundamentals check: 2026H1 revenue RMB 24.088 billion (+136.3%), net profit attributable to parent RMB 10.577 billion (only RMB 14.77 million a year earlier), ex-non-recurring RMB 10.047 billion; gross margin 58.9% (vs. 13.0% a year earlier). Red flags: inventory RMB 25.78 billion, 60% of total assets; H1 operating cash flow −RMB 3.151 billion; debt ratio 56.1% — in a price-hike cycle inventory is the profit engine; in a price drop it becomes an impairment minefield; full strong-cycle exposure. PE-TTM ~11.6x (classic low-PE trap at cycle peak).
• Industry position: domestic independent memory module leader (embedded + SSD + mobile storage, full category).
• Technicals / sentiment: ChiNext ±20%; 9/30 −3.12%.
• Final call: the fastest riser and fastest faller in memory beta; suitable for small-position observation, strictly defend the 9/30 low, not a heavy-position basis; on 10/8, beware overdrawn if the gap-up exceeds 10%.

56 胜宏科技300476total 70, watch closely · Victory Giant Technology · ChiNext

• Related news: NVIDIA record high + AI server "component shortage wave"; the company's August survey said "AI orders strong, backlog growing" (STCN⁴⁰).
• Positive logic: Direct. AI PCB (HDI high-layer) fully tied to NVIDIA chain boom.
• Industry branch stage: the elasticity core of the PCB repair branch (±20%).
• Fundamentals check: 2026H1 revenue RMB 11.629 billion (+28.8%), net profit attributable to parent RMB 2.857 billion (+33.3%), ex-non-recurring RMB 2.418 billion; operating cash flow RMB 2.911 billion; debt ratio 39.9%. Red flags: gross margin 33.2%, −3pct y/y (lagged passthrough of CCL/copper foil price hikes); high share of AI key customers (specific ratio undisclosed, unconfirmed).
• Industry position: A-share AI PCB leader, main HDI high-layer supplier.
• Technicals / sentiment: ChiNext ±20%; 9/30 −2.98%; its H shares rose >5% on 10/5 (A/H linkage).
• Final call: first choice for repair-branch elasticity, but before the gross-margin inflection (price-hike passthrough landing) earnings elasticity is limited; on 10/8 watch auction volume and volatility tolerance under the 20CM profile.

57 沪电股份002463total 70, watch closely · WUS Printed Circuit · Shenzhen main board

• Related news: NVIDIA chain high-layer board orders full; AI servers and switches dual-driven.
• Positive logic: Direct. Core AI server / 800G switch PCB supplier.
• Industry branch stage: the core anchor of the PCB repair branch.
• Fundamentals check: 2026H1 revenue RMB 13.689 billion (+61.2%), net profit attributable to parent RMB 2.923 billion (+73.7%), gross margin 38.7%, ROE 17.4% (H1 caliber); healthy financial structure.
• Industry position: one of the domestic AI high-layer PCB duopoly (alongside Victory Giant).
• Technicals / sentiment: Shenzhen main board ±10%; 9/30 followed the sector down.
• Final call: the best "earnings certainty / volatility" ratio among main-board names in the repair branch; observe as a pair with Shengyi Technology (materials + manufacturing).

58 中远海能600026total 68, watch closely · COSCO Shipping Energy · Shanghai main board

• Related news: Latest available VLCC TCE (week of 9/18) averaged US$631k/day, +42.3% w/w, intra-Gulf broke US$1 million/day (10jqka / Clarksons data¹²); around 9/17 TD3C single-day TCE was ~US$656k/day (Sina repost¹³); JPMorgan reiterates "Overweight" on H shares, TP HK$29 (Zhitong¹⁴); EIA on 10/7 raised its 2026 Brent forecast to US$96.32. The latest TCE value for the week of 10/2 is not yet available (National Day holiday) — this branch's first data gap for continued tracking.
• Positive logic: Direct, and forward indicators already extreme — the Q3-on freight rate jump goes straight into Q3 reports.
• Industry branch stage: oil-tanker super-boom continuation phase; Q4 peak season upside option.
• Fundamentals check: 2026H1 revenue RMB 15.146 billion (+30.0%), net profit attributable to parent RMB 4.545 billion (+143.2%), gross margin 41.4% (~+18pct y/y), operating cash flow RMB 6.962 billion; world's #1 oil tanker fleet (157 vessels / 23.448 million DWT). PE-TTM ~16.8x.
• Industry position: the absolute A-share oil-tanker leader.
• Technicals / sentiment: 9/30 +1.43%, steady, not overheated; main board ±10%.
• Final call: the hardest forward data but the "oldest" catalyst; the sentiment drag from Brent breaking US$100 has been realized — on 10/8 a low open is instead a mispricing watch point between freight-rate logic and oil sentiment; don't chase, watch pullback support, and wait for the week-of-10/2 TCE and VLCC spot rate updates.

59 紫金矿业601899total 68, watch closely · Zijin Mining · Shanghai main board

• Related news: On weak nonfarm payrolls + European politics, gold rebounded +0.78% in the 10/6 Asian session to ~US$4,172 (TradingEconomics⁴¹); verification correction: gold is NOT at a new high — US$4,170 is the old October 2025 high; current gold has pulled back ~26% from the January 2026 peak of US$5,595 and is about −6% over the past month, a rebound from a low within the month.
• Positive logic: Direct. The gold rebound thickens earnings (each +US$100/oz, based on ~105 tonnes annual output, adds ~RMB 2.5–3.0 billion to annual profit, estimate caliber); copper provides a second curve but with a short-term production cut.
• Industry branch stage: tug-of-war between gold's month-low rebound and copper production cuts.
• Fundamentals check: 2026H1 revenue RMB 194.178 billion (+15.8%), net profit attributable to parent RMB 39.17 billion (+68.2%), gross margin 37.8%, operating cash flow RMB 55.47 billion; H1 mined gold 47 tonnes (+13%), mined copper 534k tonnes (−5.7%, Kamoa cut; full-year plan cut from 380k–420k tonnes to 290k–330k tonnes). PE-TTM ~11.7x.
• Industry position: global top-5 gold & copper miner, #1 domestically.
• Technicals / sentiment: 9/30 +1.12%, steady; main board ±10%.
• Final call: solid fundamentals + low valuation, but the "gold at new highs" narrative doesn't hold; this list downgrades it from "new-high elasticity" to "low-position rebound + earnings delivery" watch; the copper cut is a medium-term negative. Pre-10/8 watch: tonight's Fed minutes + Treasury auctions as a guide for gold.

510 澜起科技688008total 67, watch closely · Montage Technology · STAR Market

• Related news: Micron 512GB DDR5 RDIMM sampling, 1γ LPDDR6 sampling + AI server memory capacity upgrades (Micron IR³); DDR5 penetration keeps rising.
• Positive logic: Direct. Memory interface chips (RCD/DB) are mandatory for DDR5 modules; DDR5 RDIMM volume ramps at Micron and peers directly pull its supporting shipments; AI servers bring both RCD usage and value up.
• Industry branch stage: the "pick-and-shovel seller" of the memory branch; pace follows downstream module makers.
• Fundamentals check: 2026H1 revenue RMB 3.335 billion (+26.7%), net profit attributable to parent RMB 1.997 billion (+72.3%), gross margin 65.3%, ROE 10.7% (H1 caliber); high earnings quality (net profit growth > revenue growth, gross margin stable up).
• Industry position: global memory interface chip leader (one of the main global DDR5 RCD suppliers).
• Technicals / sentiment: STAR Market ±20%; 9/30 followed semis down.
• Final call: the middle gear in the memory main line — "less elastic than Longsys, more certain than Longsys"; suitable as the branch's second observation anchor; verification point is its linkage strength with GigaDevice on 10/8.

6. Pass List

7. Intra-Branch Ranking

Innovative drugs / BD overseas + CRO + mRNA vaccine re-rating (S-tier branch)

Hardest stock: Hengrui Medicine; highest trading recognizability: CanSino Biologics; sympathy: Vland Biotech (603739), Kangchen Pharma (603590), Kangtai Biological (300601); Pass: Zhifei Biological, JenKem Technology, optogenetics concepts (Fosun Pharma (600196) et al.).

Memory supercycle (S−-tier branch, newly established in this list)

Hardest stock: GigaDevice; highest recognizability: Longsys (±20%); sympathy: back-row module/distribution names; avoid: pure-concept memory stocks. Note the "strong servers, weak consumer" structure — prefer names with high AI/server exposure.

AI computing hardware / PCB-CCL repair (A-tier branch)

Hardest stocks: Shengyi Technology / WUS Printed Circuit; highest recognizability: Victory Giant Technology; sympathy: CCL tier-2; avoid: Aohong Electronics (605058), Xiehe Electronics (605258) (fading high-flyers).

Gold (B+ tier branch)

Branch characterization: gold is a "rebound from a low within the month," not a new high; branch beta hinges on tonight's Fed minutes + Treasury auctions; if gold weakens again, the whole branch is down-weighted.

Oil tanker shipping / oil & gas (B+ tier branch)

Verification points: Brent reclaiming US$100 + the latest weekly VLCC TCE (week-of-10/2 data not yet available); if both are weak, the branch is down-weighted further.

8. Opening Verification Signals for Tomorrow (10/8, first post-holiday day)

Remaining verification windows today (10/7) (last information sources before the 10/8 open):

• HK full session on 10/7 (9:30–16:00): last holiday trading day — watch whether HK innovative-drug H shares can rise across the board for a second straight day (whether CanSino H holds HK$40), whether Kingboard Laminates repairs after the divergence, whether the Hang Seng Index reclaims 24400, whether Hengrui H stops falling;
• Tonight's US session (ET 10/7): three Treasury auctions + the Fed minutes (early Thursday morning Beijing time) — if the 10Y falls toward 5.20%, the opening environment for growth branches (innovative drugs/memory/PCB) improves; if it rallies toward 5.40%, this list's §0 down-weighting condition triggers and high-valuation branches are down-weighted across the board; a Nasdaq turn lower also presses;
• Nobel Chemistry Prize at 10/7 17:45: if it lands on gene editing/sequencing, related concepts will be knowable before the 10/8 open — treat as a C-grade pulse, do not upgrade;
• Evening of 10/7 – morning of 10/8: whether any leading company rushes out Q3 pre-announcements (first post-holiday Q3 report: Wohua Pharma (002107) on 10/10); MOF's RMB 150 billion special treasury bond auction on 10/8 — watch PBOC open-market coordination.

Auction signals:

• Innovative drugs: Hengrui gap-up ≤3% = healthy; CanSino (STAR Market ±20%) gap-up above 8% — beware profit-taking; only a thick auction seal (>20% of 9/30 full-day turnover) counts as a surprise; if Hengrui opens lower = institutions doubt BD durability, big gap-up profit-taking risk for the sector.
• Memory: gap-up size + auction volume for GigaDevice/Longsys — gap-up ≤4% with auction turnover above 10% of the 9/30 full day is strong; gap-up above 8% is overdrawn, especially Longsys (±20%).
• PCB: Shengyi gap-up ≤3% + 3 or more sector names broadly up with volume = valid repair; gap-up ≥5% = overdrawn.

Sector signals: ① Pharma: CanSino/Trinomab quick seal + Hengrui/WuXi rising on volume = main line confirmed; only back rows (Meinuohua et al.) spiking while the anchors don't move = fade warning. ② Memory: GigaDevice + Longsys + Montage firing together = new branch confirmed; only one spiking = one-day US-earnings mapping. ③ PCB: Shengyi/WUS/Victory Giant moving together + Innolight stabilizing = repair spreading; only Kinwong alone = HK-mapping inertia.

Stock signals: top-5 follow-through (auction volume / seal ratio), quick seals that don't blow, large-order net inflow, whether a stronger stock takes the baton (Trinomab squeezing out CanSino = money abandoning the high for the low).

Risk signals: ① Macro: 10Y UST charging 5.40%, Nasdaq turning lower tonight; ② standalone signals: pharma "single limit-up + back rows not following," memory/PCB "gap-up fade + shrinking volume"; ③ sentiment: Xinhua Media (600825) one-way nuke = pre-holiday sentiment high-flyers collectively cooling; Shenzhen Properties A (000011) gap-up fade = avoid the property chain; ④ volume: holiday HK thin volume (HK$98.2 billion) — if 10/8 A-share turnover cannot quickly return above RMB 1.4 trillion (9/30 full day ~RMB 1.44 trillion), the rebound's sustainability is in question.

9. Final Recommendation Conclusions

The following is only a pre-market observation priority ranking, not investment advice; all "verification points" are observation calibers, not operating instructions.

① The 5 most noteworthy stocks for the 10/8 pre-market

② The 3 strongest branches for the 10/8 pre-market

③ Directions not to chase for the 10/8 pre-market + reasons

• Chasing oil tankers/oil & gas: VLCC data is hard, but Brent has broken US$100 (closed 98.23 on 10/6) and the sentiment drag has been realized; COSCO Shipping Energy (600026) — watch pullback support only.
• Vaccine / pharma back rows: US-vaccine-mapping names like Zhifei Biological (300122, H1 loss RMB 0.8 billion), JenKem Technology (688356, LNP 2.36% of revenue) — mapping diverges from fundamentals.
• Quantum / optogenetics Nobel concepts: the Physics Prize is already falsified (neutrino astronomy); medicine-prize mappings are all indirect holdings + early pipelines; Jinyao Pharma (600488)'s missed bet is the cautionary tale.
• Cinema chains: 6 holiday days only RMB 1 billion, sharply weak y/y; post-holiday is the payoff node.
• Pre-holiday sentiment high-flyers: Xinhua Media (600825) 7 limit-ups, Shenzhen Properties A (000011) 3 boards, solid-state battery high-flyers (Chuanyi Technology (002866) / Times Wanheng (600241)) — 8 holiday days means the ladder must break; relaying high-flyers is dangerous.
• PCB mapping names gapping up ≥5%: HK already diverged first (Kingboard fell on 10/6); the biggest gap-up casualty will be the A/H mapping names (Kinwong Electronic (603228)).

④ Final one-line judgment: 10/8 will most likely gap up, but the triple signal of "Hengrui H pullback + thin HK volume + 5.31% UST" makes this a structural gap-up, not a broad one — innovative drugs and memory are the dual main lines; auction volume and gap-up size determine "repair or profit-taking"; better to miss than to be wrong.

⚠️ Risk warning: this list is only pre-market information organization and observation, not investment advice. A-share volatility risk is extremely high; automatically generated content may have information timeliness gaps or industry-chain mapping errors and must not be used directly as a trading basis.